Impact of Biomarker Heterogeneity on Pediatric Migraine Pathophysiology and Treatment
DOI:
https://doi.org/10.58445/rars.4266Keywords:
pediatric migraines, biomarker hetereogeneity, personalized care, migraine pathophysiology, diagnosticsAbstract
Pediatric migraine affects roughly 10% of children and adolescents worldwide, representing a significant cause of reduced quality of life. Current diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) is based on clinical symptoms. This approach may not entirely capture the physiology underlying migraine phenotype, severity, frequency, and treatment response due to the heterogeneity of biomarkers. Biomarkers may therefore complement clinical assessment by providing objective measures of biological processes underlying pediatric migraine. This literature review evaluates the current evidence for biomarkers associated with the pathophysiology and clinical characteristics of pediatric migraine and assesses their potential utility in diagnosis and patient characterization. PubMed and Google Scholar were searched for primary research studies and review articles examining biomarkers associated with pediatric migraine pathophysiology, clinical presentation, diagnosis, and treatment; the literature review emphasized studies published within the past ten years. The literature tracked the following biomarker classes: neuropeptides, inflammatory biomarkers, metabolic and mitochondrial biomarkers, oxidative-stress biomarkers, vitamin-related biomarkers, microRNAs, and vascular biomarkers. These findings identify several potential biomarker candidates (e.g. CGRP, inflammatory biomarkers) that may complement clinical assessment and, when evaluated in combination, may contribute to a multimarker diagnostic tool for pediatric migraine. Future research should prioritize larger longitudinal pediatric studies and standardized biomarker measurements to better translate biomarker profiles to clinically useful diagnostic and treatment strategies.
References
Pescador Ruschel, M. A., & De Jesus, O. (2024). Migraine headache. StatPearls Publishing. PubMed. https://www.ncbi.nlm.nih.gov/books/NBK560787/
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiological reviews, 97(2), 553–622. https://doi.org/10.1152/physrev.00034.2015
Thomsen, A. V., Ashina, H., Al-Khazali, H. M., Rose, K., Christensen, R. H., Amin, F. M., & Ashina, M. (2024). Clinical features of migraine with aura: a REFORM study. The Journal of Headache and Pain, 25(1), 22. https://doi.org/10.1186/s10194-024-01718-1
Khan, J., Al Asoom, L. I., Al Sunni, A., Rafique, N., Latif, R., Al Saif, S., Almandil, N. B., Almohazey, D., AbdulAzeez, S., & Borgio, J. F. (2021). Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomedicine & Pharmacotherapy, 139, 111557. https://doi.org/10.1016/j.biopha.2021.111557
Christensen, R. H., Ashina, H., & Ashina, M. (2025). The vessel-to-neuron trigeminovascular hypothesis of migraine pathogenesis – The ‘pro’ argument. The Journal of Headache and Pain, 26, 248. https://doi.org/10.1186/s10194-025-02130-z
Zhang, X., Levy, D., Kainz, V., Noseda, R., Jakubowski, M., & Burstein, R. (2011). Activation of central trigeminovascular neurons by cortical spreading depression. Annals of Neurology, 69(5), 855–865. https://doi.org/10.1002/ana.22329
Headache Classification Committee of the International Headache Society (IHS). (2018). 1. Migraine. International Classification of Headache Disorders, 3rd edition (ICHD-3). https://ichd-3.org/1-migraine/
Patterson Gentile, C., Hershey, A. D., & Szperka, C. L. (2024). A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross-sectional headache registry study in youth. Headache, 64(10), 1217–1229. https://doi.org/10.1111/head.14858
D. Asuncion, R. M., Al Khalili, Y., & Chopra, P. (2023). Migraine headache in childhood. StatPearls Publishing. PubMed. https://www.ncbi.nlm.nih.gov/books/NBK557813/
Al-Beltagi M. (2026). Pediatric migraine: Neurodevelopmental mechanisms, clinical phenotypes, and modern therapeutics. World Journal of Clinical Pediatrics, 15(2), 119843. https://doi.org/10.5409/wjcp.v15.i2.119843
Headache Classification Committee of the International Headache Society (IHS). (2018). Migraine without aura. The International Classification of Headache Disorders (3rd ed.). https://ichd-3.org/1-migraine/1-1-migraine-without-aura/
Eigenbrodt, A. K., Ashina, H., Khan, S., Diener, H. C., Mitsikostas, D. D., Sinclair, A. J., Pozo-Rosich, P., Martelletti, P., Ducros, A., Lantéri-Minet, M., Braschinsky, M., Del Rio, M. S., Daniel, O., Özge, A., Mammadbayli, A., Arons, M., Skorobogatykh, K., Romanenko, V., Terwindt, G. M., Paemeleire, K., Ashina, M. (2021). Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 17(8), 501–514. https://doi.org/10.1038/s41582-021-00509-5
Demartini, C., Francavilla, M., Zanaboni, A. M., Facchetti, S., De Icco, R., Martinelli, D., Allena, M., Greco, R., & Tassorelli, C. (2023). Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings. International Journal of Molecular Sciences, 24(6), 5334. https://doi.org/10.3390/ijms24065334
Monte, G., Granata, C., Ursitti, F., Sforza, G., Valeriani, M., & Papetti, L. (2026). Migraine in pediatric population: the role of biochemical markers. The Journal of Headache and Pain, 27(1), 96. https://doi.org/10.1186/s10194-026-02344-9
Tajti, J., Szok, D., Majláth, Z., Tuka, B., Csáti, A., & Vécsei, L. (2015). Migraine and neuropeptides. Neuropeptides, 52, 19–30. https://doi.org/10.1016/j.npep.2015.03.006
Stuchfield-Denby, E., Pereira, B., Bouvier, D., Dallel, R., & Moisset, X. (2025). Distinct inflammatory profiles across migraine states: a systematic review and meta-analysis. The Journal of Headache and Pain, 26(1), 219. https://doi.org/10.1186/s10194-025-02136-7
Vo, D. K., & Trinh, K. T. L. (2024). Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis. International Journal of Molecular Sciences, 25(23), 13190. https://doi.org/10.3390/ijms252313190
Gross, E. C., Lisicki, M., Fischer, D., Sándor, P. S., & Schoenen, J. (2019). The metabolic face of migraine - from pathophysiology to treatment. Nature Reviews Neurology, 15(11), 627–643. https://doi.org/10.1038/s41582-019-0255-4
Gaul, C., Diener, H. C., Danesch, U., & Migravent® Study Group (2015). Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. The Journal of Headache and Pain, 16, 516. https://doi.org/10.1186/s10194-015-0516-6
Grodzka, O., Słyk, S., & Domitrz, I. (2023). The Role of MicroRNA in Migraine: A Systemic Literature Review. Cellular and Molecular Neurobiology, 43(7), 3315–3327. https://doi.org/10.1007/s10571-023-01387-9
Hoffmann, J., Baca, S. M., & Akerman, S. (2019). Neurovascular mechanisms of migraine and cluster headache. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 39(4), 573–594. https://doi.org/10.1177/0271678X17733655
Russo A. F. (2017). Overview of Neuropeptides: Awakening the Senses?. Headache, 57 Suppl 2(Suppl 2), 37–46. https://doi.org/10.1111/head.13084
Catalani, E., De Palma, C., Perrotta, C., & Cervia, D. (2017). Current Evidence for a Role of Neuropeptides in the Regulation of Autophagy. BioMed Research International, 2017, 5856071. https://doi.org/10.1155/2017/5856071
Russell, F. A., King, R., Smillie, S. J., Kodji, X., & Brain, S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiological Reviews, 94(4), 1099–1142. https://doi.org/10.1152/physrev.00034.2013
Russo A. F. (2015). Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual Review of Pharmacology and Toxicology, 55, 533–552. https://doi.org/10.1146/annurev-pharmtox-010814-124701
Karpiesiuk, A., & Palus, K. (2021). Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Physiological and Pathological Processes within the Gastrointestinal Tract: A Review. International Journal of Molecular Sciences, 22(16), 8682. https://doi.org/10.3390/ijms22168682
Rubio-Beltrán, E., Correnti, E., Deen, M., Kamm, K., Kelderman, T., Papetti, L., Vigneri, S., MaassenVanDenBrink, A., Edvinsson, L., & European Headache Federation School of Advanced Studies (EHF-SAS) (2018). PACAP38 and PAC1 receptor blockade: a new target for headache?. The Journal of Headache and Pain, 19(1), 64. https://doi.org/10.1186/s10194-018-0893-8
Delgado, M., & Ganea, D. (2013). Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids, 45(1), 25–39. https://doi.org/10.1007/s00726-011-1184-8
Tanaka, M., Szabó, Á., Körtési, T., Szok, D., Tajti, J., & Vécsei, L. (2023). From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment. Cells, 12(22), 2649. https://doi.org/10.3390/cells12222649
Graefe, S., & Mohiuddin, S. S. (2023, July 30). Biochemistry, Substance P. StatPearls Publishing. PubMed. https://www.ncbi.nlm.nih.gov/books/NBK554583/
Liu, J., Wang, G., Dan, Y., & Liu, X. (2022). CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. The Journal of Headache and Pain, 23(1). https://doi.org/10.1186/s10194-022-01435-7
Hanci F, Kilinc YB, Kilinc E, Turay S, Dilek M, Kabakus N. Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods. Cephalalgia, 41(2), 166-175. https://doi.org/10.1177/0333102420957588
Al-Karagholi, M. A., Zhuang, Z. A., Beich, S., Ashina, H., & Ashina, M. (2025). PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial. The Journal of Headache and Pain, 26(1), 79. https://doi.org/10.1186/s10194-025-02022-2
Orak, S. A., Polat, M., Pak, M., Çerçi Kubur, Ç., Atasever, A. K., Yilmaz, C., Taneli, F., Angin, A., & Cengiz Özyurt, B. (2025). Can serum neuropeptide levels help diagnose pediatric migraine? A prospective case-control study. Headache, 65(10), 1821–1830. https://doi.org/10.1111/head.14981
Fusayasu, E., Kowa, H., Takeshima, T., Nakaso, K., & Nakashima, K. (2007). Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain, 128(3), 209–214. https://doi.org/10.1016/j.pain.2006.09.017
Alpay, B., Christensen, R. H., Al-Khazali, H. M., Ashina, M., & Ashina, H. (2025). Substance P and the trigeminovascular system: From preclinical mechanisms to human headache induction. Cephalalgia, 45(8). https://doi.org/10.1177/03331024251355944
Chavda, V. P., Feehan, J., & Apostolopoulos, V. (2024). Inflammation: The Cause of All Diseases. Cells, 13(22), 1906. https://doi.org/10.3390/cells13221906
Morgan, C. T., & Nkadimeng, S. M. (2025). The Role of Inflammation in Migraine Headaches: A Review. FASEB BioAdvances, 7(7), e70033. https://doi.org/10.1096/fba.2024-00188
Cavalli, G., Colafrancesco, S., Emmi, G., Imazio, M., Lopalco, G., Maggio, M. C., Sota, J., & Dinarello, C. A. (2021). Interleukin 1α: A comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews, 20(3), 102763. https://doi.org/10.1016/j.autrev.2021.102763
Grebenciucova, E., & VanHaerents, S. (2023). Interleukin 6: At the interface of human health and disease. Frontiers in Immunology, 14, 1255533. https://doi.org/10.3389/fimmu.2023.1255533
Syed, E. U. R., Nazar, N., & Reddy, N. J. (2025). Serum inflammatory cytokines as biomarkers for predicting chronic migraine transformation: a systematic review of randomized controlled trials. Annals of medicine and surgery (2012), 87(12), 8779–8788. https://doi.org/10.1097/MS9.0000000000004121
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020). A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorganic & medicinal chemistry, 28(5), 115327. https://doi.org/10.1016/j.bmc.2020.115327
Gonzalez Caldito N. (2023). Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. Frontiers in immunology, 14, 1213448. https://doi.org/10.3389/fimmu.2023.1213448
Singh, B., Goyal, A., & Patel, B. C. (2025). C-reactive protein: Clinical relevance and interpretation. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK441843/
Inoue, K., Kodama, T., & Daida, H. (2012). Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. International journal of vascular medicine, 2012, 657025. https://doi.org/10.1155/2012/657025
Gonthupuli, S. K., Ponnaiyan, D., Anitha, C. M., Prakash, P. S. G., Victor, D. J., & Verma, N. (2026). Serum and salivary calcitonin gene-related peptide, pentraxin-3 and interleukin-1β levels in patients with periodontitis suffering from migraines. World Academy of Sciences Journal, 8, 1-12. https://doi.org/10.3892/wasj.2026.438
Boćkowski, L., Sobaniec, W., & Żelazowska-Rutkowska, B. (2009). Proinflammatory plasma cytokines in children with migraine. Pediatric Neurology, 41(1), 17–21. https://doi.org/10.1016/j.pediatrneurol.2009.02.001
Khan, A., Liu, S., & Tao, F. (2025). Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategies. Brain Sciences, 15(3), 280. https://doi.org/10.3390/brainsci15030280
Qiu, S., Cai, Y., Yao, H., Zhou, B., Shi, X., & Ke, B. (2023). Small molecule metabolites: Discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy, 8, 132. https://doi.org/10.1038/s41392-023-01399-3
Grech, O., Sassani, M., Terwindt, G., Lavery, G. G., Mollan, S. P., & Sinclair, A. J. (2022). Alterations in metabolic flux in migraine and the translational relevance. The journal of headache and pain, 23(1), 127. https://doi.org/10.1186/s10194-022-01494-w
Santangelo, D., Lobianco, C., Burrafato, R. E., Tosto, F., Magro, G., & Pascarella, A. (2026). Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms. Journal of clinical medicine, 15(4), 1476. https://doi.org/10.3390/jcm15041476
Fila, M., Chojnacki, J., Pawlowska, E., Szczepanska, J., Chojnacki, C., & Blasiak, J. (2021). Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders. International journal of molecular sciences, 22(18), 10134. https://doi.org/10.3390/ijms221810134
Kozák, M., Sitku, T., Hodossy-Takács, R., Sápi, F., Várkonyi, I., & Barta, Z. (2026). Migraine and the Gut–Brain Axis–The Role of Microbiome-Targeted Biotics. Nutrients, 18(5), 720. https://doi.org/10.3390/nu18050720
Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L. R., & Scaldaferri, F. (2024). Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Internal and emergency medicine, 19(2), 275–293. https://doi.org/10.1007/s11739-023-03374-w
Liu, J., Xi, K., Zhang, L., Han, M., Wang, Q., & Liu, X. (2024). Tryptophan metabolites and gut microbiota play an important role in pediatric migraine diagnosis. The Journal of Headache and Pain, 25(1), 2. https://doi.org/10.1186/s10194-023-01708-9
Shayota B. J. (2024). Biomarkers of mitochondrial disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 21(1), e00325. https://doi.org/10.1016/j.neurot.2024.e00325
Fan, Y.-L., Dai, F.-Y., Wang, J.-Y., Dai, X.-Y., Song, W.-L., Wu, H., Gao, S.-J., Tao, M., Zhang, L.-Q., Liu, T.-Z., Yang, S.-G., Liu, D.-Q., Zhou, Y.-Q., & Mei, W. (2026). Mitochondrial dysfunction as a driver of chronic pain: New insights and therapeutic prospects. Pharmacological Research, 227, 108170. https://doi.org/10.1016/j.phrs.2026.108170
Sun, W., Chen, T., Song, M., Gao, Y., & Xu, S. (2025). Energy metabolism disorders in migraine: Triggers, pathways, and therapeutic repurposing. Frontiers in Neurology, 16, 1561000. https://doi.org/10.3389/fneur.2025.1561000
Wischhusen, J., Melero, I., & Fridman, W. H. (2020). Growth/differentiation factor-15 (GDF-15): From biomarker to novel targetable immune checkpoint. Frontiers in Immunology, 11, 951. https://doi.org/10.3389/fimmu.2020.00951
Burow, P., Haselier, M., Naegel, S., Scholle, L. M., Gaul, C., & Kraya, T. (2021). The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine. Cells, 10(9), 2471. https://doi.org/10.3390/cells10092471
Xie, T., & Leung, P. S. (2017). Fibroblast growth factor 21: a regulator of metabolic disease and health span. American journal of physiology. Endocrinology and metabolism, 313(3), E292–E302. https://doi.org/10.1152/ajpendo.00101.2017
Liang, J., Du, X., Wang, M., Zheng, H., Sun, Y., & Lin, Y. (2025). Association Between Hypoxia-Inducible Factor-1α and Neurological Diseases: A Bidirectional Two-Sample Mendelian Randomization Analysis. Brain and behavior, 15(3), e70398. https://doi.org/10.1002/brb3.70398
Kılınç, Y. B., Kılınç, E., Daniş, A., et al. (2023). Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1α are elevated in pediatric migraine attacks. Headache, 63, 1076–1086. https://doi.org/10.1111/head.14618
Fila, M., Chojnacki, C., Chojnacki, J., & Blasiak, J. (2021). Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine. Nutrients, 13(12), 4433. https://doi.org/10.3390/nu13124433
Sood, B., Patel, P., & Keenaghan, M. (2024). Coenzyme Q10. StatPearls. StatPearls Publishing.
Hershey, A. D., Powers, S. W., Vockell, A.-L. B., LeCates, S. L., Ellinor, P. L., Segers, A., Burdine, D., Manning, P., & Kabbouche, M. A. (2007). Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache: The Journal of Head and Face Pain, 47(1), 73–80. https://doi.org/10.1111/j.1526-4610.2007.00652.x
Gallelli, L., Cione, E., Peltrone, F., Siviglia, S., Verano, A., Chirchiglia, D., Zampogna, S., Guidetti, V., Sammartino, L., Montana, A., Caroleo, M. C., De Sarro, G., & Di Mizio, G. (2019). Hsa-miR-34a-5p and hsa-miR-375 as Biomarkers for Monitoring the Effects of Drug Treatment for Migraine Pain in Children and Adolescents: A Pilot Study. Journal of Clinical Medicine, 8(7), 928. https://doi.org/10.3390/jcm8070928
Paolucci, M., Altamura, C., & Vernieri, F. (2021). The Role of Endothelial Dysfunction in the Pathophysiology and Cerebrovascular Effects of Migraine: A Narrative Review. Journal of clinical neurology (Seoul, Korea), 17(2), 164–175. https://doi.org/10.3988/jcn.2021.17.2.164
Aczél, T., Benczik, B., Ágg, B., Körtési, T., Urbán, P., Bauer, W., Gyenesei, A., Tuka, B., Tajti, J., Ferdinandy, P., Vécsei, L., Bölcskei, K., Kun, J., & Helyes, Z. (2022). Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: Role of inflammatory signalling and oxidative stress. The Journal of Headache and Pain, 23, 113. https://doi.org/10.1186/s10194-022-01478-w
Hadjikhani, N., & Vincent, M. (2019). Neuroimaging clues of migraine aura. The journal of headache and pain, 20(1), 32. https://doi.org/10.1186/s10194-019-0983-2
Spekker, E., Tanaka, M., Szabó, Á., & Vécsei, L. (2022). Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research. Biomedicines, 10(1), 76. https://doi.org/10.3390/biomedicines10010076
Sekelj Fures, J., Duranovic, V., Lenicek Krleza, J., Katusic Bojanac, A., Loncar, L., Dakovic, I., Pejic-Rosko, S., Vulin, K., Pilon-Far, A., & Simic Klaric, A. (2024). Calcitonin-Gene-Related Peptide in Migraine and Tension-Type Headache in Children During Interictal Period. Diagnostics, 14(23), 2645. https://doi.org/10.3390/diagnostics14232645
Rossi, H. L., & Recober, A. (2015). Photophobia in primary headaches. Headache, 55(4), 600–604. https://doi.org/10.1111/head.12532
Ramírez-Expósito, M. J., Cueto-Ureña, C., & Martínez-Martos, J. M. (2026). Calcitonin Gene-Related Peptide (CGRP): Biology, Signaling, Pathophysiological Roles, and Therapeutic Applications. International Journal of Molecular Sciences, 27(11), 4973. https://doi.org/10.3390/ijms27114973
Bernstein, C., & Burstein, R. (2012). Sensitization of the trigeminovascular pathway: Perspective and implications to migraine pathophysiology. Journal of Clinical Neurology, 8(2), 89–99. https://doi.org/10.3988/jcn.2012.8.2.89
Şahin, Ş. S., Hataysal, E. P., Karatoprak, E. Y., Ovalı, F., Özel, A., Durankuş, F., & Vatansev, H. (2025). Tryptophan metabolism in children with migraine: The role of kynurenine pathway. Brain & development, 47(3), 104359. https://doi.org/10.1016/j.braindev.2025.104359
Rivera-Mancilla, E., Villalón, C. M., & MaassenVanDenBrink, A. (2020). CGRP inhibitors for migraine prophylaxis: a safety review. Expert opinion on drug safety, 19(10), 1237–1250. https://doi.org/10.1080/14740338.2020.1811229
Edvinsson, L. (2018). The CGRP pathway in migraine as a viable target for therapies. Headache: The Journal of Head and Face Pain, 58(Suppl. 1), 33–47. https://doi.org/10.1111/head.13305
Schoenen, J., Van Dycke, A., Versijpt, J., & Paemeleire, K. (2023). Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: A narrative review. The Journal of Headache and Pain, 24(1), Article 99. https://doi.org/10.1186/s10194-023-01637-7
Edvinsson, L. (2025). Is PACAP the next big thing in migraine therapy? Cephalalgia, 45(8). https://doi.org/10.1177/03331024251368748
Ashina, M., Phul, R., Khodaie, M., Löf, E., & Florea, I. (2024). A monoclonal antibody to PACAP for migraine prevention. New England Journal of Medicine, 391(9), 800–809. https://doi.org/10.1056/NEJMoa2314577
Slater, S. K., Nelson, T. D., Kabbouche, M. A., LeCates, S. L., Horn, P., Segers, A., Manning, P., Powers, S. W., & Hershey, A. D. (2011). A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia, 31(8), 897–905. https://doi.org/10.1177/0333102411406755
Fallah, R., Sarraf Yazd, S., & Sohrevardi, S. M. (2020). Efficacy of Topiramate Alone and Topiramate Plus Vitamin D3 in the Prophylaxis of Pediatric Migraine: A Randomized Clinical Trial. Iranian journal of child neurology, 14(4), 77–86.
Fan, P. C., Chua, H. H., Lin, C. R., Lai, T. H., Chiou, L. C., Lee, W. T., Chen, H. L., & Ni, Y. H. (2026). Targeting the microbiome in pediatric migraine: gastrointestinal manifestations and the therapeutic role of Bifidobacterium longum. Gut microbes, 18(1), 2606487. https://doi.org/10.1080/19490976.2025.2606487
Raucci, U., Boni, A., Evangelisti, M., Della Vecchia, N., Velardi, M., Ursitti, F., Terrin, G., Di Nardo, G., Reale, A., Villani, A., & Parisi, P. (2021). Lifestyle modifications to help prevent headache at a developmental age. Frontiers in Neurology, 11, 618375. https://doi.org/10.3389/fneur.2020.618375
Kamm, K., Straube, A., & Ruscheweyh, R. (2019). Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia : an international journal of headache, 39(12), 1535–1543. https://doi.org/10.1177/0333102419856640
Novikov, V. N., Danilov, A. B., Kosareva, A. D., & Kulish, K. K. (2025). Portable device for determination of CGRP in tears (Russian Patent No. RU2838426C1). Google Patents. https://patents.google.com/patent/RU2838426C1/en
Yang, J., Luo, R., Yang, L., Wang, X., & Huang, Y. (2023). Microneedle-Integrated Sensors for Extraction of Skin Interstitial Fluid and Metabolic Analysis. International journal of molecular sciences, 24(12), 9882. https://doi.org/10.3390/ijms24129882
Vora, L. K., Sabri, A. H., McKenna, P. E., Donnelly, R. F., & collaborators. (2024). Microneedle-based biosensing. Nature Reviews Bioengineering, 2, 64–81. https://doi.org/10.1038/s44222-023-00108-7
Li, X., Zhang, C., Zhang, Y., Liu, Z., Li, J., Meng, Y., & Zhang, P. (2025). Microneedles in biomedicine: Innovations, challenges, and future prospects. Biomaterials translational, 6(4), 373–388. https://doi.org/10.12336/bmt.25.00122
Downloads
Posted
Categories
License
Copyright (c) 2026 Research Archive of Rising Scholars
This work is licensed under a Creative Commons Attribution 4.0 International License.
